Interim Report January-June 2013 ChronTech Pharma
· Research and development costs amounted to SEK 0.9 (6.7) m · The loss after tax was SEK -3.6 (-9.6) m · Earnings per share were SEK -0.02 (-0.05) · The company had no net sales for the period · ChronTech Pharma has received a bridge loan of 625 TUSD · At the extra general meeting (EGM) in ChronTech Pharma AB on the 16th of May it was resolved to accept the board’s proposal for restructuring of the company and transfer of the Company’s projects regarding development of DNA-vaccines against hepatitis B and hepatitis C. · ChronTech holds the 20-percentage ownership in